TY - JOUR
T1 - Muscle fat index is associated with frailty and length of hospital stay following transcatheter aortic valve replacement in high-risk patients
AU - Heidari, Behnam
AU - Ahmad, Ali
AU - Al-Hijji, Mohammed A.
AU - Aoun, Joe
AU - Singh, Mandeep
AU - Moynagh, Michael R.
AU - Takahashi, Naoki
AU - Lerman, Lilach O.
AU - Alkhouli, Mohamad A.
AU - Lerman, Amir
N1 - Funding Information:
None.
Publisher Copyright:
© 2021
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Background: Aging is associated with progressive loss of muscle mass, as well as replacement of muscle with fat and fibrous tissue. We studied the contribution of muscle fat content, a surrogate marker of biological aging, to frailty and Length of Hospital Stay (LOS) following Transcatheter Aortic Valve Replacement (TAVR). Methods: We evaluated 415 patients who underwent TAVR from February 2012 to December 2016 at Mayo Clinic, MN, USA. Densities between −190 to −30 Hounsfield Units within the abdominal muscle area were determined as muscle fat. Muscle Fat Index (MFI) was defined as muscle fat mass divided by height squared. LOS was considered as the primary outcome. Stepwise multivariable linear regression was used to identify the predictors of LOS. Results: Mean age ± SD of the study population was 81.2 ± 9.6 years and 58.07% were male. Seventy-two patients (17.35%) had frailty. Median (IQR) LOS was 4 (3–6) days. MFI was higher in patients with frailty (median (IQR); 18.1 [13.8–24.2] vs 14.4 [10.6–18.7], p < 0.001) and was positively correlated with LOS (r = 0.129, p = 0.009). In multivariable analysis of predictors of LOS, MFI (β = 0.06, p = 0.022), pre-TAVR atrial fibrillation/flutter (β = 0.5, p = 0.015), and post-TAVR complications (β = 0.91, p < 0.001) were directly, and femoral access route (β = −1.13, p < 0.001) and pre-TAVR hemoglobin (β = −0.35, p = 0.002) were inversely associated with LOS. Conclusions: MFI can be determined from pre-TAVR CT scans and is a novel predictor of LOS following TAVR. This objective indicator can potentially be used in a pre-TAVR clinic to plan for rehabilitation programs in selected patients.
AB - Background: Aging is associated with progressive loss of muscle mass, as well as replacement of muscle with fat and fibrous tissue. We studied the contribution of muscle fat content, a surrogate marker of biological aging, to frailty and Length of Hospital Stay (LOS) following Transcatheter Aortic Valve Replacement (TAVR). Methods: We evaluated 415 patients who underwent TAVR from February 2012 to December 2016 at Mayo Clinic, MN, USA. Densities between −190 to −30 Hounsfield Units within the abdominal muscle area were determined as muscle fat. Muscle Fat Index (MFI) was defined as muscle fat mass divided by height squared. LOS was considered as the primary outcome. Stepwise multivariable linear regression was used to identify the predictors of LOS. Results: Mean age ± SD of the study population was 81.2 ± 9.6 years and 58.07% were male. Seventy-two patients (17.35%) had frailty. Median (IQR) LOS was 4 (3–6) days. MFI was higher in patients with frailty (median (IQR); 18.1 [13.8–24.2] vs 14.4 [10.6–18.7], p < 0.001) and was positively correlated with LOS (r = 0.129, p = 0.009). In multivariable analysis of predictors of LOS, MFI (β = 0.06, p = 0.022), pre-TAVR atrial fibrillation/flutter (β = 0.5, p = 0.015), and post-TAVR complications (β = 0.91, p < 0.001) were directly, and femoral access route (β = −1.13, p < 0.001) and pre-TAVR hemoglobin (β = −0.35, p = 0.002) were inversely associated with LOS. Conclusions: MFI can be determined from pre-TAVR CT scans and is a novel predictor of LOS following TAVR. This objective indicator can potentially be used in a pre-TAVR clinic to plan for rehabilitation programs in selected patients.
KW - Adipose tissue
KW - Aging
KW - Aortic stenosis
KW - Frailty
KW - Muscle
KW - Muscle fat
KW - Transcatheter aortic valve implantation
UR - http://www.scopus.com/inward/record.url?scp=85121272394&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121272394&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2021.11.087
DO - 10.1016/j.ijcard.2021.11.087
M3 - Article
C2 - 34871623
AN - SCOPUS:85121272394
SN - 0167-5273
VL - 348
SP - 33
EP - 38
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -